Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.42 |
| ▸ | BRAF | P15056 | 9/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127061 | 0.92 | CYP3A4 (0.53) | CYP3A4MAPK14BRAFCDK9LYN | |
| SCHEMBL2128420 | 0.91 | CYP3A4 (0.53) | CYP3A4MAPK14BRAFBTKLYN | |
| SCHEMBL2127623 | 0.91 | CYP3A4 (0.53) | CYP3A4MAPK14BRAFBTKLYN | |
| SCHEMBL1542369 | 0.89 | CYP3A4 (0.65) | CYP3A4MAPK14CDK9BTKALDH1A1 | |
| SCHEMBL1542627 | 0.86 | CYP3A4 (0.44) | CYP3A4BTKALDH1A1MEN1KMT2A | |
| SCHEMBL2129460 | 0.86 | CYP3A4 (0.59) | CYP3A4MAPK14BTKALDH1A1MEN1 | |
| SCHEMBL1542202 | 0.83 | CYP3A4 (0.60) | CYP3A4MAPK14ALDH1A1MEN1KMT2A | |
| SCHEMBL1542657 | 0.83 | CYP3A4 (0.49) | CYP3A4BTKALDH1A1MEN1KMT2A | |
| SCHEMBL1542748 | 0.82 | CYP3A4 (0.47) | CYP3A4BTKALDH1A1MEN1KMT2A | |
| SCHEMBL1542477 | 0.81 | CYP3A4 (0.59) | CYP3A4MAPK14BRAFCDK9LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | claimed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | claimed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | CYP3A4 528/4885MAPK14 3995/4885BRAF 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.